Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study
Authors:
- Yutaka YasuiYYYutaka Yasui
- Masayuki KurosakiMKMasayuki Kurosaki
- Kaoru TsuchiyaKTKaoru Tsuchiya
- Yuka HayakawaYHYuka Hayakawa
- Chitomi HasebeCHChitomi Hasebe
- Masami AbeMAMasami Abe
- Chikara OgawaCOChikara Ogawa
- Kouji JokoKJKouji Joko
- Hironori OchiHOHironori Ochi
- Toshifumi TadaToshifumi Tada
- Shinichiro NakamuraSNShinichiro Nakamura
- Koichiro FurutaKFKoichiro Furuta
Open Access
Abstract
Background: The present study aimed to clarify the efficacy and safety of ramucirumab in a real-world setting, including patients who experienced two or more systemic treatments or whose hepatic reserve was deteriorated. Methods: In total, 79 patients with hepatocellular carcinoma (HCC) from 14 institutes throughout Japan were retrospectively analyzed. The response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and AEs were recorded according to the Common Terminology Criteria for AEs (CTCAE) version 5.0. Results: Median overall survival (OS) in the total cohort was 7.5 months (m). Median OS was 8.8 m in patients who were administered ramucirumab as a second-line treatment, while it was 7.3 m in third- or later-line treatment. Progression-free survival rates in the second- and third- or later-line therapies were 3.2 m and 3.2 m, respectively. The disease control rate (DCR) in the study was 43%. There were no statistically significant differences in DCR between the treatment courses. Regarding adverse events (AEs), the development of ascites was observed significantly more frequently in modified albumin–bilirubin (mALBI) 2b/3 patients than in mALBI 1/2a patients (54.5% vs. 25.0%, p = 0.03). Conclusions: Ramucirumab is useful as a second-line therapy and feasible as a third- or later-line treatment for HCC.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP20fk0210067h0001)
This publication has 35 references indexed in Scilit:
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular CarcinomaNew England Journal of Medicine, 2018
- Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real‐world practiceHepatology Research, 2018
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular CarcinomaJAMA Oncology, 2017
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trialJournal of Gastroenterology, 2016
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialThe Lancet Oncology, 2015
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008